Richard Bungay, an experienced biotech executive, has joined Imophoron Ltd as chief executive. Imophoron has a nanoparticle technology for vaccines. Mr Bungay was previously CEO of Diurnal Group Plc where he led the recent sale of the company to Neurocrine Biosciences Inc in the US. He has also served as chief financial and chief operating officer at Mereo Biopharma Group Plc and CEO of Chroma Therapeutics Ltd. He is a chartered accountant with a degree in chemistry from Nottingham University in the UK.
Imophoron announced the appointment on 14 November 2022.
Copyright 2022 Evernow Publishing Ltd